StudyFinder



Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with LG IR NMIBC.

Administered locally via standard catheters, UGN-102 is designed to fill and conform to the anatomy of the bladder and dwell for a period of several hours before being excreted via normal urine flow.

Jay Raman
UrologyResearch@pennstatehealth.psu.edu
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05243550
SITE00001122
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Low Grade Bladder Cancer
Requiring treatment with TURBT
Multiple tumors
Tumor >3cm
Tumor recurrence within 1 year
Exclusion Criteria:
Received BCG within previous 1 year
History of High Grade bladder Cancer in past 2 years
Sensitivity to mitomycin
Neurogenic bladder
Significant urethral stricture precluding passage of urethral catheter
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,